Authorized purpose: Cartesion Prime is a PET/CT system for acquisition, reconstruction, fusion, visualization, and professional interpretation within the cleared configuration and radiopharmaceutical workflow.
Clinical role
PET/CT acquisition, reconstruction, attenuation correction, fusion, visualization, and professional review support.
Images and patients
PET/SPECT/Nuclear Medicine · Multi-region
Key limitation
Keep in mind: Radiopharmaceutical, scan range, patient-size, acquisition, reconstruction, attenuation-correction, dose, and quantitative limits are configuration-specific. Cartesion Prime is a PET/CT system for acquisition, reconstruction, fusion, visualization, and professional interpretation within the cleared configuration and radiopharmaceutical workflow.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Cartesion Prime is a PET/CT system for acquisition, reconstruction, fusion, visualization, and professional interpretation within the cleared configuration and radiopharmaceutical workflow.
Which images or clinical context are in scope?Modality: PET/SPECT/Nuclear Medicine Anatomy or clinical context: Multi-region Input: Positron-emission data, CT transmission data, patient information, protocol information, and supported radiopharmaceutical studies.
Who uses it?Intended users: Qualified nuclear medicine physicians, radiologists, technologists, and other trained PET/CT professionals.
What does the software produce?Output: PET, CT, fused PET/CT, quantitative, and planning image series for professional interpretation.
What is its most important limitation?Key limitation: Radiopharmaceutical, scan range, patient-size, acquisition, reconstruction, attenuation-correction, dose, and quantitative limits are configuration-specific. Cartesion Prime is a PET/CT system for acquisition, reconstruction, fusion, visualization, and professional interpretation within the cleared configuration and radiopharmaceutical workflow.
Clinical takeaway. Clinical role: Cartesion Prime is a PET/CT system for acquisition, reconstruction, fusion, visualization, and professional interpretation within the cleared configuration and radiopharmaceutical workflow.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports bench tests showing AiCE-i for PET significantly improved Signal to Noise Ratio and improved quantification at the same noise, NEMA NU 2-2018 phantom measurements, and an IEC Body Phantom study showing unchanged overall quantification; three physicians with at least 20 years of nuclear medicine experience judged all five patients' AiCE-i for PET images of diagnostic quality, with image quality, sharpness and noise improved versus Gaussian images (one physician rated noise about the same). Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Cartesion Prime is a PET/CT system for acquisition, reconstruction, fusion, visualization, and professional interpretation within the cleared configuration and radiopharmaceutical workflow.
Radiopharmaceutical, scan range, patient-size, acquisition, reconstruction, attenuation-correction, dose, and quantitative limits are configuration-specific. Cartesion Prime is a PET/CT system for acquisition, reconstruction, fusion, visualization, and professional interpretation within the cleared configuration and radiopharmaceutical workflow.
The exact FDA document reports bench tests showing AiCE-i for PET significantly improved Signal to Noise Ratio and improved quantification at the same noise, NEMA NU 2-2018 phantom measurements, and an IEC Body Phantom study showing unchanged overall quantification; three physicians with at least 20 years of nuclear medicine experience judged all five patients' AiCE-i for PET images of diagnostic quality, with image quality, sharpness and noise improved versus Gaussian images (one physician rated noise about the same). Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "A series of bench tests were conducted to support marketing claims associated with image quality, quantification accuracy, count dependency, and preservation of quantification. As demonstrated in these studies, AiCE-i for PET significantly improved Signal to Noise Ratio, improved quantification at the same noise" … "Through the phantom experiment following NEMA NU 2-2018, the basic performance of AiCE-i for PET is measured.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports bench tests showing AiCE-i for PET significantly improved Signal to Noise Ratio and improved quantification at the same noise, NEMA NU 2-2018 phantom measurements, and an IEC Body Phantom study showing unchanged overall quantification; three physicians with at least 20 years of nuclear medicine experience judged all five patients' AiCE-i for PET images of diagnostic quality, with image quality, sharpness and noise improved versus Gaussian images (one physician rated noise about the same). Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "A series of bench tests were conducted to support marketing claims associated with image quality, quantification accuracy, count dependency, and preservation of quantification. As demonstrated in these studies, AiCE-i for PET significantly improved Signal to Noise Ratio, improved quantification at the same noise" … "Through the phantom experiment following NEMA NU 2-2018, the basic performance of AiCE-i for PET is measured.". Read from the exact FDA decision document on 2026-11-14.
No exact submission and version-linked sensitivity endpoint is published in this dossier; do not substitute a product-family or candidate-study value.
Reported specificity
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No exact submission and version-linked specificity endpoint is published in this dossier; do not substitute a product-family or candidate-study value.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
FDA submission-specific verification and validation evidence for K203314
DesignRegulatory verification, validation, and labeling evidence reviewed for exact FDA submission K203314.
PopulationThe labeled population and test materials for exact submission K203314; a general clinical study population is not established here.
Scopeexact submission
Tested versionCartesion Prime (PCD-1000A/3) V10.8 (K203314)
IndependenceSponsor or vendor study
K203314
FDA regulatory evidence is submission-specific but is not independent clinical performance evidence.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
FDA recall Z-0142-2022 is associated with native exact submission identifier K203314. Status: Terminated. Product: Canon PET-CT SCANNER, Cartesion Prime, MODEL PCD-1000A. Reason: A software problem has been identified which could result in the diagnostic imaging system not proceeding to the next actual scan even though automatic start of the next scan is specified. This could result in the diagnostic imaging system failing resulting in rescanning and reinjection of contrast medium.
FDA source
Exact FDA submission
Checked 2026-09-04
Each published event was manually matched to the exact FDA submission and affected product or version; a recall does not establish an AI-algorithm defect or current site exposure unless the event states that scope.
Native exact-submission identifier match from the openFDA candidate snapshot accessed 2026-09-04 with source snapshot date 2026-09-02. Source URL: https://api.fda.gov/device/recall.json?search=product_res_number.exact%3A%22Z-0142-2022%22&limit=1. This does not establish exact installed serial, lot, unit, or software-version applicability.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Positron-emission data, CT transmission data, patient information, protocol information, and supported radiopharmaceutical studies.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. Exact submission evidence and the current vendor family material do not establish the exact site's DICOM, worklist, PACS/RIS, identity, routing, display, or fallback behavior.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-04 ·
AI processing
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. Exact deployment topology, hosting, network boundaries, update mechanism, and local operational requirements are not established for this submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-04 ·
Returned objects
Source context, not route validation: PET, CT, fused PET/CT, quantitative, and planning image series for professional interpretation.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: PET, CT, fused PET/CT, quantitative, and planning image series for professional interpretation.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Canon Medical's cybersecurity page states that Canon imaging systems follow a software development life cycle governed by the NIST 800-53 Risk Management Framework adhering to Defense Health Agency certification requirements; FIPS 140-2 certified cipher standards; deny-all firewall configuration and near-real-time SIEM syslog export as premium offerings; a dedicated cybersecurity risk management team for threat intelligence monitoring, advisories and incident response; and published OS and third-party update policies. Vendor statement; no certification or test report was read.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: the page is on us.medical.canon, Canon Medical's own site (Canon Medical Systems USA), and describes Canon Medical imaging devices generally; the FDA applicant is Canon Medical Systems Corporation, named in the corporate name-change press release on the same domain. Regional page with general device claims; exact-release scope is not established.
Current vendor material is product-family context for K203314 only; exact release, enabled options, deployment, and local interoperability require confirmation.
product family · checked 2026-09-04
Vendor material is not exact-release evidence unless that linkage is separately proven.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-04Last searched
29Fields reviewed
13Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. 1 FDA recall candidate was manually reviewed: 1 published and 0 rejected as a neighboring or otherwise inapplicable version. Native FDA recall identifiers produced 1 postmarket candidate record; 1 has been reviewed (1 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, vendor product page, implementation documentation, reimbursement policy, peer reviewed literature, clinical trial registry, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public exact-release price, license fee, subscription, contract, or implementation cost was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not applicable - checked 2026-09-04 - Not applicable
CMS index context was checked, but no product-specific coverage or reimbursement determination is inferred.
Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission
Exact deployment topology, hosting, network boundaries, update mechanism, and local operational requirements are not established for this submission.
Integration: Not publicly available - checked 2026-09-04 - Exact FDA submission
Exact submission evidence and the current vendor family material do not establish the exact site's DICOM, worklist, PACS/RIS, identity, routing, display, or fallback behavior.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-10-27 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: BIOGRAPH One with syngo MR XB10 combines metabolic or physiologic PET information with MR anatomy, MR-based attenuation correction, fused alignment, and support for treatment planning and interventions.
Authorized purpose: Voxel Dosimetry 3.1 calculates voxel-level absorbed-dose maps from nuclear-medicine images acquired after administration of FDA-approved therapeutic radiopharmaceuticals and supports single-time-point or time-series workflows.
Authorized purpose: syngo.via MI Workflows, Scenium, and syngo MBF provide PET, SPECT, nuclear-medicine, CT, and MR viewing, manipulation, quantification, longitudinal comparison, and analysis for oncology, cardiology, neurology, organ function, and selected radiation-planning support.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.